Medivir to release Phase 2a HCC study data in Q3 report.

NORDIC BUSINESS REPORT-October 25, 2023-Medivir to release Phase 2a HCC study data in Q3 report

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Pharmaceutical company Medivir AB (Nasdaq Stockholm: MVIR) announced on Wednesday that it is set to disclose new and updated data from its ongoing phase 2a study featuring fostrox in combination with Lenvima for advanced hepatocellular carcinoma (HCC). The update will focus on 18 of 21 patients with a minimum 12-week follow-up. This information will be part of Medivir's Q3 interim report on 27 October 2023, followed by a webcasted presentation at 14:00 CET.

The company aims to discuss how these data enhance the potential of fostrox + Lenvima in transforming second-line HCC treatment, where no approved medical treatments exist post current standard care. Medivir will outline the clinical benefits in this high-unmet medical need population, highlighting the potential for expedited approval and commercial success.

The webcast, hosted by Medivir's CEO Jens Lindberg and team...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT